Healius Ltd (ASX:HLS) has become the latest healthcare stock to unsettle investors, with the pathology provider plunging to fresh all-time lows after downgrading earnings guidance and warning deteriorating conditions across the sector were squeezing margins harder than expected.
Shares in the ASX-listed pathology services company fell as much as 20% on Wednesday after the company cut FY26 underlying EBITDA guidance to $259 million–264 million, below market expectations of roughly $271 million, while underlying EBIT guidance of $30 million–35 million came in well short of forecasts.
Compressed gas transport and storage company Provaris Energy Ltd (ASX:PV1, OTC:GBBLF, FRA:WS90) says Germany’s newly approved renewable transport fuel mandate could mark a major turning point for Europe’s emerging green hydrogen import market, with the company positioning its compressed hydrogen shipping model as a potential solution to looming supply shortfalls.
In a new investor note, the company points to Germany’s formal adoption of the European Union’s Renewable Energy Directive III (RED III) into national law on May 8 as a particularly significant development for the sector.
Conico Ltd (ASX:CNJ) has applied for two new exploration licences in East Greenland, adding the Kai rare earths project and Lilloise gold-platinum group elements (Au-PGE) project to its regional portfolio.
The applications sit adjacent to Conico’s 100%-owned Ryberg Project and, if granted, would lift the company’s Greenland landholding to about 6,460 square kilometres, making it one of the largest landholders in East Greenland.
Neurizon Therapeutics Ltd (ASX:NUZ) has received ethics approval from the Bellberry Human Research Ethics Committee for a Phase 1 formulation study of its NUZ-001 oral liquid treatment for amyotrophic lateral sclerosis (ALS).
The approval allows Neurizon to advance clinical work on an oral liquid version of NUZ-001, which is being developed to improve treatment access and flexibility for people living with ALS.
Nexsen Ltd (ASX:NXN) has secured its first hospital partner in Asia after signing a binding term sheet with GHK Hospital Ltd, operator of Gleneagles Hospital Hong Kong, to support clinical validation and potential commercial adoption of its rapid point-of-care diagnostics platform.
Nexsen is developing rapid point-of-care diagnostics designed to deliver lab-grade results closer to the patient, reducing reliance on slower laboratory testing.
Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) could be significantly undervalued as its focused push into allogeneic CAR-T therapy gathers momentum, according to a new initiation report from RaaS Research, which has assigned the company a risk-adjusted valuation of $0.24 per share — representing 129% upside to the current share price of $0.105.
The broker believes the market is yet to fully appreciate Imugene’s strategic transformation into a streamlined CAR-T-focused biotech centred on its lead asset azer-cel, an “off-the-shelf” allogeneic CAR-T therapy targeting blood cancers.
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has strengthened its board with the appointments of experienced healthcare and finance executive Susan Knight and company veteran Stephen Denaro as directors.
Knight joins as a Class I director, serving through to the company’s 2028 annual meeting, and will also sit on the audit and risk committee. Denaro returns to the board as a Class II director with a term running until the 2026 annual meeting.
American Rare Earths Ltd (ASX:ARR, OTCQX:ARRNF) has formally started the process towards a planned Nasdaq listing, appointing BDO Audit Pty Ltd as its new auditor as the company continues positioning its Halleck Creek rare earths project as part of a broader US critical minerals supply chain strategy.
The company said BDO’s appointment took effect from May 12 and was made to support its planned US Nasdaq listing, which it is targeting for the second half of calendar year 2026.
Lightning Minerals Ltd (ASX:L1M, FRA:YZ1) has expanded its technical and corporate leadership team as the company pushes ahead with a strategic reset centred on Australian gold exploration, appointing experienced geoscientist and corporate executive Andrew Lambert as exploration and corporate development manager.
The appointment comes less than a month after Lightning repositioned itself around its Mt Turner Gold Project in north Queensland, shifting away from its earlier lithium focus to become a gold-led exploration and development company.
Atomic Eagle Ltd (ASX:AEU, FRA:6QZ0) has expanded the high-grade southwest zone at the Chisebuka target within its 100%-owned Muntanga Uranium Project in Zambia, with 13 of the first 15 holes in a 2026 drilling program intersecting uranium mineralisation outside the current resource area.
The first 15 holes, comprising 1,540 metres of drilling, form part of a planned 30,000-metre campaign targeting resource growth across Chisebuka, Namakande and Muntanga North.
Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has reported strong operational progress for the March 2026 quarter as the company advanced recruitment for its global PARADIGM pivotal trial and strengthened its balance sheet with US$320 million in capital raises.
The structural heart company said the funding completed in January would support execution of the PARADIGM Trial and accelerate the path toward global commercialisation of its DurAVR® transcatheter heart valve (THV) system.
Resource Minerals International Ltd (ASX:RMI) is gearing up for a 2,500-metre reverse circulation (RC) drilling program at its 100%-owned Mpanda Copper-Gold Project in Tanzania in early June after securing Coreworthy Drilling (T) Ltd as contractor.
The staged campaign will test five priority targets — Stalike, Ibindi, Kabungu, Kabungu North and Kabatini West — selected from integrated geological mapping, geochemical sampling, historical drilling, rock chip results and high-resolution drone magnetic interpretation.